Long-Term Effects Of Atrial Shunt Device On Cardiac Structure And Function In Heart Failure With Preserved And Mildly Reduced Ejection Fraction: Results From The REDUCE LAP-HF II Randomized Clinical Trial

Sanjiv J. Shah

DOI: https://doi.org/10.1016/j.cardfail.2023.10.469

IF: 6.592

2024-01-01

Journal of Cardiac Failure

Abstract:Background Several atrial shunt devices and procedures are in development for patients with heart failure (HF), including those with HF and preserved ejection fraction (HFpEF), with the goal of decreasing left atrial (LA) pressure at rest and during exertion in these patients. A number of phase 3 trials of atrial shunts in HF are ongoing; however, to date, only 1 large, randomized, sham-controlled pivotal trial (REDUCE LAP-HF II, which studied the Corvia Atrial Shunt Device [8-mm diameter]) has been completed. The overall REDUCE LAP-HF II trial was neutral, but responder analyses indicated that approximately 50% of patients enrolled in the trial (who had peak exercise PVR <1.74 WU and no pacemaker/ICD) benefited from atrial shunting, with lower HF events and improvement in health status compared to placebo. A confirmatory randomized trial (RESPONDER-HF) is underway to validate these results. Nevertheless, there is debate about the long-term effects of left-to-right shunting on cardiac structure/function (especially the right ventricle [RV]), and whether an 8-mm shunt size is too large, thereby resulting in progressive RV enlargement and/or dysfunction. Objectives We sought to determine the long-term effects (up to 24 months) of the Corvia Atrial Shunt Device on cardiac structure/function compared to a sham procedure. Methods REDUCE LAP-HF II (n=626) was a multi-center, randomized, sham-controlled, blinded trial in patients with HF, LVEF ≥40%, and peak exercise PCWP ≥25 mmHg. Comprehensive echo was performed at baseline and at 1-, 6-, 12-, and 24-month follow-up intervals, and interpreted by a central echo core lab blinded to treatment status. Changes from baseline to follow-up in echo indices were analyzed within each treatment group (using paired-tests) and between treatment groups (using linear regression, controlling for the baseline value). Mixed models for repeated measures (MMRM) analyses were used to evaluate between-group differences in echo indices over time. Cardiac chamber volumes, LV systolic and diastolic function, RV function, LV and RV tissue velocities, hemodynamics, Qp:Qs, LA function, and mitral and tricuspid regurgitation severity were analyzed at each time point. Exploratory analyses were performed to evaluate whether changes in cardiac structure/function over time differed by responder vs. non-responder status. Results The REDUCE LAP-HF II echo completion rate was high (88%, 86%, 85%, and 76% at 1-, 6-, 12-, and 24-mo., respectively). All echo measurements at each time point have been completed, and the results of the comprehensive REDUCE LAP-HF II echo analyses will be available in time for the HFSA Scientific Sessions. Conclusions Detailed and comprehensive long-term echo data from REDUCE LAP-HF II provide important insights into the effects of atrial shunt treatment (vs. sham control) on cardiac structure/function over time. These results have implications for the entire field of shunt devices and procedures, which remain an intensive area of investigation in patients with HF.

cardiac & cardiovascular systems